Midazolam intranasal - Upsher-Smith

Drug Profile

Midazolam intranasal - Upsher-Smith

Alternative Names: ITI-111; USL-261

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Intranasal Therapeutics
  • Developer Upsher-Smith
  • Class Benzodiazepines; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Seizures
  • New Molecular Entity No

Highest Development Phases

  • Phase III Seizures
  • Phase I Epilepsy
  • Discontinued Anaesthesia; Anxiety disorders; Mild cognitive impairment

Most Recent Events

  • 28 Oct 2016 Phase-I clinical trials in Epilepsy (In children) (Intranasal) before October 2016
  • 28 Oct 2016 Pharmacokinetics and safety data from a phase I trial in Seizures released by Upsher-Smith
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top